141 results on '"Voloshin T"'
Search Results
2. PI3K Inhibition Sensitized Cancerous Cells to Tumor Treating Fields (TTFields)
3. Enhancing Cancer Cell Membrane Permeability by Application of Tumor Treating Fields (TTFields)
4. Tumor Treating Fields (TTFields) Delivery to Macrophages Promotes a Pro-Inflammatory Phenotype
5. P10.11.B Re-sensitizing cancer cells to Tumor Treating Fields (TTFields) through PI3K/AKT/mTOR pathway inhibition
6. EP16.01-016 Tumor Treating Fields (TTFields) Application Promotes a Pro-inflammatory Phenotype in Macrophages
7. EP16.03-028 Cancer Cells May be Re-sensitized to Tumor Treating Fields (TTFields) Through Inhibition of the PI3K/AKT/mTOR Pathway
8. P10.01.A Reversible blood-brain barrier (BBB) disruption by Tumor Treating Fields (TTFields) in a human 3Din vitro model
9. P-121 Effects of tumor treating fields (TTFields) on gastric cancer cells and their potential concomitant application with FOLFOX
10. Impact of Tumor Treating Fields (TTFields) on DNA Damage Repair in Mesothelioma
11. Mechanism of Action of Tumor Treating Fields (TTFields) in Combination with Sorafenib for Treatment of Hepatocellular Carcinoma
12. Activated Phosphoinositide 3-Kinase/AKT/mTOR Signaling Confers Resistance to Tumor Treating Fields (TTFields)
13. FP07.04 Effect of Tumor Treating Fields (TTFields) on DNA Damage and The FA-BRCA DNA Repair Pathway in Mesothelioma
14. Tumor Treating Fields (TTFields) application to cancerous cell lines elevates membrane permeability
15. P-184 Underlining mechanism for the efficacy of tumor treating fields (TTFields) concomitant with sorafenib for treatment of hepatocellular carcinoma
16. Cancer cell permeability is increased after Tumor Treating Fields (TTFields) application
17. Application of Tumor Treating Fields (TTFields) to open the blood brain barrier (BBB) as future CNS drug delivery strategy
18. P25.09 Effectiveness of Tumor Treating Fields plus Cisplatin/Pemetrexed Combination in Mesothelioma, in Vitro and in Vivo
19. P-99 Tumor treating fields (TTFields) are effective for treatment of gastric cancer cells, boosting the activity of FOLFOX
20. Effectiveness and Safety of Tumor Treating Fields (150 kHz) plus Cisplatin or Pemetrexed Combination in Mesothelioma: in Vitro and in Vivo Findings
21. Safety and Effectiveness of Tumor Treating Fields (TTFields; 150 kHz) and Sorafenib Combination Treatment in Hepatocellular Carcinoma In Vitro and In Vivo
22. P-261 Safety and effectiveness of tumor treating fields combined with sorafenib in preclinical models of hepatocellular carcinoma
23. P-255 Effects of tumor treating fields (150 kHz) in combination with FOLFOX on gastric cancer cells in vitro
24. P1.06-17 Tumor Treating Fields (150 kHz) Combined with Cisplatin or Pemetrexed Inhibits Mesothelioma Cells in Vitro and in Vivo
25. EP1.06-07 In Vivo Studies of Tumor Treating Fields to Upper Torso in Combination with Chemotherapy Show No Additional Toxicities
26. Effects of tumor treating fields (TTFields; 150 kHz) and cisplatin or pemetrexed combination therapy on mesothelioma cells in vitro and in vivo
27. Tumor Treating Fields (TTFields) Plus Sorafenib Is Safe and Effective in Hepatocellular Carcinoma Tested in Vitro and in an Animal Model
28. Immunogenic Cell Death Induced by Tumor Treating Fields (TTFields) Enhances Efficacy When Combined with Anti-PD-1 Therapy in Lung and Colon Cancer Animal Models
29. Blood Brain Barrier (BBB) Integrity Is Affected By Tumor Treating Fields (TTFields) in Vitro and In Vivo
30. Animal Studies Evaluating the Safety of Tumor Treating Fields (TTFields) Alone and in Combination with Chemotherapy Agents Demonstrate No Additional Toxicities
31. Efficacy of Tumor Treating Fields (TTFields) in Combination with Cisplatin or Pemetrexed for the Treatment of Mesothelioma in Vitro and in Vivo
32. The Combined Treatment of 150 kHz Tumor Treating Fields (TTFields) and FOLFOX Inhibit Gastric Cancer in Vitro
33. The combined treatment of 150 kHz Tumor Treating Fields (TTFields) and sorafenib shows In vitro and in vivo efficacy in hepatocellular carcinoma
34. Tumor Treating Fields (150 kHz) combined with FOLFOX inhibits gastric cancer in vitro
35. The Combined Treatment of 150 kHz Tumor Treating Fields (TTFields) and Cisplatin or Pemetrexed Inhibit Mesothelioma Cells In Vitro
36. P04.55 Efficacy of Tumor Treating Fields (TTFields) and aurora B kinase inhibitor
37. P02.04 Tumor treating fields induce immunogenic cell death resulting in enhanced antitumor efficacy when combined with anti-PD-1 therapy
38. P04.16 Tumor treating fields affect invasion properties and cell morphology of various cancer cells
39. P04.15 Autophagy induction following TTFields application serves as a survival mechanism mediated by AMPK signaling
40. Tumor Treating Fields (TTFields) Delay DNA Damage Repair Following Radiation Treatment of Glioma Cells: Implications for Irradiation Through TTFields Transducer Arrays
41. 1852P - Effects of tumor treating fields (TTFields; 150 kHz) and cisplatin or pemetrexed combination therapy on mesothelioma cells in vitro and in vivo
42. Efficacy of tumor treating fields (TTFields) and anti-PD-1 in non-small-cell lung cancer (NSCLC) preclinical models
43. Efficacy of Tumor Treating Fields (TTFields) and anti-PD-1 in non-small cell lung cancer (NSCLC) preclinical models
44. P-250 - The combined treatment of 150 kHz Tumor Treating Fields (TTFields) and sorafenib shows In vitro and in vivo efficacy in hepatocellular carcinoma
45. P-228 - Tumor Treating Fields (150 kHz) combined with FOLFOX inhibits gastric cancer in vitro
46. Immunomodulatory Effect of Tumor Treating Fields (TTFields) Results in Enhanced Antitumor Efficacy When Combined with Anti-PD-1 Therapy in Mouse Model of Lung Cancer
47. Tumor Treating Fields (TTFields) Sensitize Glioma Tumor Cells to Radiation Therapy by Delaying DNA Damage Repair Through Homologous Recombination
48. 1206P - Efficacy of tumor treating fields (TTFields) and anti-PD-1 in non-small-cell lung cancer (NSCLC) preclinical models
49. 39P - Efficacy of Tumor Treating Fields (TTFields) and anti-PD-1 in non-small cell lung cancer (NSCLC) preclinical models
50. Correction: Davidi et al. Tumor Treating Fields (TTFields) Concomitant with Sorafenib Inhibit Hepatocellular Carcinoma In Vitro and In Vivo . Cancers 2022, 14 , 2959.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.